ERBB2 and cancer: To overcome the limitations of traditional HER2 blockade, Antibody-Drug Conjugates (ADCs) have recently emerged as a transformative therapeutic modality for HER2-positive metastatic GC, offering a novel mechanism to deliver potent cytotoxicity directly to cancer cells (11, 14).